You are here: Industry Insights > Karolinska

News List

Cobra Bio, Karolinska Inst. to Develop COVID-19 Vaccine contractpharma
March 31, 2020
Cobra Biologics, an international contract development and manufacturing organization (CDMO) for biologics and pharmaceuticals, and the Karolinska Institutet ...
Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin firstwordpharma
February 24, 2019
Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics, safety and tolerability of subcutaneous sevuparin injections in healthy a
RXi and Karolinska Institutet target solid tumour therapy pharmaceutical-technology
August 17, 2018
US-based biotechnology company RXi Pharmaceuticals has formed a research alliance with the Karolinska Institutet in Stockholm, Sweden, to develop and improve immuno-oncology treatments for solid tumours.
Karolinska Development company Modus Therapeutics raises SEK 32 million to support development of se firstwordpharma
February 21, 2017
Karolinska Development AB has successfully completed a financing round raising SEK 32 million (USD 3.6 million) from existing investors KDev Investments, Östersjöstiftelsen and Praktikerinvest.
NeuroVive Signs Collaboration Agreement with Karolinska Institutet americanpharmaceuticalreview
January 11, 2017
NeuroVive Pharmaceutical announced that a collaboration agreement has been signed with Karolinska Institutet, Stockholm, Sweden, regarding development of the company's compound NV556 for the treatment of mitochondrial myopathy.